An “early signature”, characterized by the expression of genes related to tumor suppressor activities, and associated with the longer survival of HCC patients, and a “late signature” that includes a set of genes related to TGF-β tumor promoter effects such as positive regulators of cell cycle and EMT. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.